Author:
Salem Kelley,McCormick Michael L.,Wendlandt Erik,Zhan Fenghuang,Goel Apollina
Funder
NIH
Leukemia & Lymphoma Society Translational Research Program
Subject
Organic Chemistry,Biochemistry,Clinical Biochemistry
Reference89 articles.
1. Cancer statistics, 2014;Siegel;CA Cancer Journal for Clinicians,2014
2. P.L. Bergsagel, Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma 2014, American Society of Clinical Oncology Educational Book/ASCO American Society of Clinical Oncology Meeting, 2014, pp. 199–203.
3. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives;Jakubowiak;Seminars in Hematology,2012
4. Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma;Manochakian;Oncologist,2007
5. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage;Feng;British Journal of Haematology,2007
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献